Title:Adalimumab versus Infliximab Treatment Outcome in Ulcerative Colitis:
Application of EQ-5D, Visual Analogue Scale, and IBDQ-9 Measures:
A Prospective Observational Study
Volume: 18
Issue: 4
Author(s): Hassan Karami, Farbod Ebadi Fard Azar*, Kamran Bagheri Lankarani, Aziz Rezapour, Sulmaz Ghahramani and Abdolvahab Baghbanian
Affiliation:
- Health Promotion Research Center‚ Iran University of Medical Sciences‚ Tehran‚ Iran
Keywords:
Infliximab, adalimumab, ulcerative colitis, EQ-5D, ADA, IFX.
Abstract:
Background: Ulcerative colitis (UC) is a chronic global disease, and its incidence and
prevalence are increasing worldwide.
Objective: Our objective was to compare the secondary outcome of treatment with Infliximab
(IFX) and Adalimumab (ADA) in the UC patients.
Methods: This was a one-year prospective observational study of moderate- to -severe UC patients
treated with ADA or IFX. Patients' secondary health outcomes were measured using the EQ-5D
3L, EQ-VAS, and IBDQ-9 tools. T-test, Mann-Whitney, chi-square, and Fisher's exact tests were
used to compare health-related quality of life (HRQoL) among UC patients. HRQoL predictor variables
were identified by multivariate linear regression and multivariate logistic regression.
Results: A total of 238 UC patients (patients taking IFX: 78, patients taking ADA: 160) with a
mean age of 37.66 and a mean disease duration of 9.29 years were enrolled. The EQ-5D index,
EQ-VAS, and IBDQ-9 scores of patients taking IFX were 0.65, 55.93 and, 37.42, respectively.
Similarly, patients taking ADA were 0.68, 59.27 and, 36.61, respectively. The highest problem reports
were in P/D: 86.1% and A/D: 73.5%. The main independent predictors of HRQoL were: education
over 12 years (β = 0.054 [EQ-5D index], β = 13.63 [EQ-VAS], OR: 0.28 [MO], OR: 0.07
[SC]), education between 6-12 years (β = 11.23 [EQ-VAS]), and having "other chronic diseases"
(β = -0.074 [EQ-5D index], β = -5.29 [IBDQ-9], OR: 2.84 [UA], OR: 3.80 [A/D]).
Conclusion: There was no significant difference between the effect of ADA and IFX on secondary
health outcomes in patients with moderate-to-severe UC.